Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Topical niacinamide riboside, Niagen NanoCloud
Nicotinamide riboside · 1 trial · 2 indications
Days
| Arm | Type | Description |
|---|---|---|
| Nicotinamide riboside 250 mg | EXPERIMENTAL | One capsule of 250 mg each morning for three months |
| Nicotinamide riboside 500 mg | EXPERIMENTAL | One capsule of 250 mg each morning and afternoon for three months |
| Nicotinamide riboside 1000 mg | EXPERIMENTAL | Two capsules of 250 mg each morning and afternoon for three months |
| Nicotinamide riboside 2000 mg | EXPERIMENTAL | Four capsules of 250 mg each morning and afternoon for three months |
| Placebo for 250 mg nicotinamide riboside | PLACEBO_COMPARATOR | One capsule each morning for three months |
| Placebo for 500 mg nicotinamide riboside | PLACEBO_COMPARATOR | One capsule each morning and afternoon for three months |
| Placebo for 1000 mg nicotinamide riboside | PLACEBO_COMPARATOR | Two capsules each morning and afternoon for three months |
| Placebo for 2000 mg nicotinamide riboside | PLACEBO_COMPARATOR | Four capsules each morning and afternoon for three months |
| Name | Type | Description |
|---|---|---|
| Nicotinamide riboside | DRUG | Nicotinamide riboside in different doses |
| Placebo | DRUG | Placebo |
Inclusion criteria: 1. Adults \> 18 years old, admitted to hospital with tissue damage, can be included when they are considered medically stable though still expected to remain hospitalized for at least 7 more days (from inclusion). 2. Preferably: Previously included in the Janus Cohort or any oth...